The team further targeted the upstream ubiquitin-binding enzyme UBE2T to develop a small molecular inhibitor M435-1279 with low cytotoxicity that can inhibit the progression of gastric cancer in vivo and in vitro (Figure 3). This evidence concerns the gene UBE2T and gastric cancer.